zenith laboratori inc said compani will report fourth quarter loss and amount will determin complet it year end audit compani did not elabor further for third quarter end sept 1986 zenith report loss 451 000 dlrs cts per share adjust for may 1986 for stock split compani also said receiv food and drug administr approv market cefadroxil generic version antibiot with domest sale exceed mln dlrs 1986 zenith said will not market drug until question relat applic certain patent have been resolv reuter 